| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Xylans | 24 | 2021 | 27 | 10.610 |
Why?
|
| Apoptosis | 26 | 2021 | 162 | 7.800 |
Why?
|
| Carcinoma, Ehrlich Tumor | 7 | 2020 | 10 | 3.720 |
Why?
|
| Dendritic Cells | 8 | 2019 | 23 | 3.620 |
Why?
|
| Breast Neoplasms | 12 | 2017 | 167 | 3.260 |
Why?
|
| Saccharomyces cerevisiae | 10 | 2019 | 16 | 3.180 |
Why?
|
| Animals | 42 | 2022 | 1238 | 3.130 |
Why?
|
| Antioxidants | 6 | 2022 | 20 | 2.910 |
Why?
|
| Oxidative Stress | 8 | 2021 | 102 | 2.820 |
Why?
|
| Antineoplastic Agents | 7 | 2020 | 61 | 2.640 |
Why?
|
| Mice | 26 | 2021 | 508 | 2.400 |
Why?
|
| Alzheimer Disease | 3 | 2021 | 14 | 2.370 |
Why?
|
| Humans | 43 | 2021 | 2493 | 2.350 |
Why?
|
| Probiotics | 4 | 2020 | 6 | 2.320 |
Why?
|
| Killer Cells, Natural | 19 | 2021 | 31 | 2.230 |
Why?
|
| Female | 36 | 2021 | 1733 | 2.210 |
Why?
|
| Cell Line, Tumor | 21 | 2020 | 138 | 1.930 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2018 | 12 | 1.900 |
Why?
|
| Paclitaxel | 4 | 2019 | 13 | 1.880 |
Why?
|
| Aging | 8 | 2020 | 101 | 1.850 |
Why?
|
| Lactobacillus | 3 | 2020 | 5 | 1.840 |
Why?
|
| Male | 27 | 2021 | 1649 | 1.810 |
Why?
|
| Liver | 4 | 2022 | 120 | 1.790 |
Why?
|
| CD4-Positive T-Lymphocytes | 7 | 2019 | 15 | 1.760 |
Why?
|
| Phagocytosis | 13 | 2008 | 15 | 1.730 |
Why?
|
| Oryza | 7 | 2020 | 7 | 1.720 |
Why?
|
| Stomach Neoplasms | 3 | 2016 | 6 | 1.650 |
Why?
|
| Cytokines | 11 | 2021 | 47 | 1.590 |
Why?
|
| Cell Proliferation | 9 | 2020 | 110 | 1.570 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2021 | 11 | 1.520 |
Why?
|
| Kefir | 2 | 2020 | 3 | 1.500 |
Why?
|
| Flow Cytometry | 15 | 2021 | 42 | 1.490 |
Why?
|
| Streptozocin | 4 | 2022 | 9 | 1.440 |
Why?
|
| Iron | 3 | 2015 | 5 | 1.380 |
Why?
|
| Carcinogenesis | 2 | 2020 | 12 | 1.320 |
Why?
|
| Adjuvants, Immunologic | 4 | 2018 | 6 | 1.190 |
Why?
|
| Lymphocyte Activation | 8 | 2018 | 18 | 1.170 |
Why?
|
| bcl-2-Associated X Protein | 7 | 2021 | 15 | 1.160 |
Why?
|
| Adenocarcinoma | 4 | 2019 | 27 | 1.130 |
Why?
|
| Platinum | 3 | 2017 | 4 | 1.090 |
Why?
|
| Antigens, CD | 7 | 2015 | 18 | 1.080 |
Why?
|
| Cells, Cultured | 10 | 2019 | 164 | 1.070 |
Why?
|
| Thymus Extracts | 3 | 2009 | 4 | 1.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 8 | 2016 | 24 | 1.060 |
Why?
|
| Iron Compounds | 2 | 2019 | 2 | 1.050 |
Why?
|
| Cultured Milk Products | 2 | 2015 | 2 | 1.050 |
Why?
|
| Cognition | 2 | 2021 | 10 | 1.030 |
Why?
|
| Minerals | 2 | 2018 | 2 | 1.010 |
Why?
|
| Nanodiamonds | 2 | 2017 | 2 | 1.000 |
Why?
|
| Spleen | 5 | 2019 | 10 | 0.990 |
Why?
|
| Dietary Supplements | 2 | 2021 | 13 | 0.990 |
Why?
|
| Rats, Wistar | 6 | 2022 | 35 | 0.990 |
Why?
|
| DNA Damage | 6 | 2020 | 16 | 0.980 |
Why?
|
| Cognitive Dysfunction | 2 | 2021 | 5 | 0.980 |
Why?
|
| Hematologic Diseases | 2 | 2013 | 3 | 0.930 |
Why?
|
| Radiation Injuries | 2 | 2013 | 4 | 0.930 |
Why?
|
| Brain | 2 | 2021 | 55 | 0.920 |
Why?
|
| Trifolium | 1 | 2022 | 1 | 0.870 |
Why?
|
| Immunity, Innate | 2 | 2021 | 8 | 0.870 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2022 | 22 | 0.850 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 1 | 0.850 |
Why?
|
| Lactobacillus sakei | 1 | 2021 | 1 | 0.850 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 2021 | 1 | 0.850 |
Why?
|
| Immunity, Mucosal | 1 | 2021 | 1 | 0.850 |
Why?
|
| Bacterial Proteins | 1 | 2021 | 3 | 0.850 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 3 | 0.850 |
Why?
|
| Intestinal Mucosa | 1 | 2021 | 8 | 0.850 |
Why?
|
| Methotrexate | 1 | 2021 | 1 | 0.840 |
Why?
|
| Placental Extracts | 1 | 2021 | 1 | 0.840 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 7 | 0.840 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2021 | 12 | 0.830 |
Why?
|
| Fermentation | 1 | 2021 | 1 | 0.830 |
Why?
|
| Placenta | 1 | 2021 | 27 | 0.820 |
Why?
|
| Neuroprotective Agents | 1 | 2021 | 6 | 0.800 |
Why?
|
| Lymphocytes | 8 | 2009 | 13 | 0.780 |
Why?
|
| Biological Products | 1 | 2020 | 1 | 0.770 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2010 | 3 | 0.770 |
Why?
|
| Immunomodulation | 1 | 2020 | 1 | 0.770 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2020 | 10 | 0.760 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 143 | 0.760 |
Why?
|
| Seawater | 2 | 2018 | 2 | 0.740 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 148 | 0.740 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2013 | 118 | 0.730 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2019 | 8 | 0.710 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2016 | 7 | 0.700 |
Why?
|
| Quality of Life | 1 | 2019 | 60 | 0.690 |
Why?
|
| Rats | 6 | 2022 | 432 | 0.690 |
Why?
|
| Cell Cycle | 4 | 2020 | 14 | 0.670 |
Why?
|
| Lectins, C-Type | 3 | 2014 | 4 | 0.660 |
Why?
|
| Paracrine Communication | 1 | 2018 | 3 | 0.650 |
Why?
|
| Biomarkers | 4 | 2021 | 58 | 0.610 |
Why?
|
| Keratinocytes | 1 | 2017 | 7 | 0.610 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2014 | 27 | 0.600 |
Why?
|
| Viremia | 1 | 2016 | 3 | 0.600 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 2 | 0.600 |
Why?
|
| Antiviral Agents | 1 | 2016 | 2 | 0.600 |
Why?
|
| Middle Aged | 9 | 2021 | 799 | 0.590 |
Why?
|
| Glutathione | 4 | 2021 | 13 | 0.590 |
Why?
|
| Radiation Tolerance | 2 | 2013 | 4 | 0.580 |
Why?
|
| Mitochondria | 4 | 2015 | 26 | 0.580 |
Why?
|
| Stomach | 1 | 2016 | 3 | 0.580 |
Why?
|
| Lipid Peroxidation | 4 | 2021 | 7 | 0.580 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2015 | 8 | 0.570 |
Why?
|
| Cytotoxicity, Immunologic | 13 | 2000 | 18 | 0.570 |
Why?
|
| Candida albicans | 3 | 2004 | 3 | 0.550 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 2 | 0.530 |
Why?
|
| Protective Agents | 1 | 2015 | 2 | 0.530 |
Why?
|
| T-Lymphocytes | 4 | 2010 | 12 | 0.530 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 18 | 0.520 |
Why?
|
| Interferon-gamma | 4 | 2016 | 18 | 0.510 |
Why?
|
| Tumor Burden | 3 | 2019 | 15 | 0.500 |
Why?
|
| Malondialdehyde | 3 | 2021 | 5 | 0.500 |
Why?
|
| Leukemia, Myeloid | 1 | 2014 | 1 | 0.500 |
Why?
|
| Double-Blind Method | 3 | 2021 | 48 | 0.490 |
Why?
|
| Caspase 3 | 3 | 2021 | 12 | 0.470 |
Why?
|
| Aged | 6 | 2021 | 607 | 0.460 |
Why?
|
| Hematopoietic System | 1 | 2013 | 2 | 0.460 |
Why?
|
| Whole-Body Irradiation | 1 | 2013 | 2 | 0.460 |
Why?
|
| Signal Transduction | 3 | 2020 | 180 | 0.460 |
Why?
|
| Immunologic Factors | 2 | 2004 | 5 | 0.450 |
Why?
|
| Membrane Potential, Mitochondrial | 4 | 2015 | 5 | 0.440 |
Why?
|
| Cell Line | 5 | 2021 | 80 | 0.430 |
Why?
|
| Calcium | 2 | 2009 | 35 | 0.430 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 1 | 0.400 |
Why?
|
| Curcumin | 1 | 2011 | 7 | 0.400 |
Why?
|
| Amyloid beta-Peptides | 2 | 2021 | 3 | 0.400 |
Why?
|
| Metal Nanoparticles | 1 | 2010 | 1 | 0.390 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 32 | 0.390 |
Why?
|
| Cell Survival | 4 | 2017 | 17 | 0.380 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 45 | 0.380 |
Why?
|
| Up-Regulation | 3 | 2021 | 71 | 0.380 |
Why?
|
| Inflammation | 2 | 2021 | 44 | 0.380 |
Why?
|
| Immune System Diseases | 1 | 2010 | 2 | 0.380 |
Why?
|
| Nanofibers | 1 | 2010 | 2 | 0.380 |
Why?
|
| Cellular Senescence | 1 | 2010 | 6 | 0.380 |
Why?
|
| Body Weight | 3 | 2019 | 65 | 0.360 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 37 | 0.340 |
Why?
|
| MCF-7 Cells | 2 | 2019 | 17 | 0.340 |
Why?
|
| Daunorubicin | 1 | 2008 | 1 | 0.330 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 17 | 0.330 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2008 | 26 | 0.330 |
Why?
|
| Phagocytes | 1 | 2008 | 1 | 0.330 |
Why?
|
| Mice, Inbred C57BL | 4 | 2010 | 185 | 0.320 |
Why?
|
| Macrophages | 2 | 2005 | 22 | 0.320 |
Why?
|
| Organ Size | 2 | 2019 | 33 | 0.320 |
Why?
|
| In Vitro Techniques | 7 | 2014 | 37 | 0.320 |
Why?
|
| Adult | 8 | 2016 | 807 | 0.310 |
Why?
|
| Yeast, Dried | 1 | 2007 | 2 | 0.310 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 2 | 2018 | 2 | 0.300 |
Why?
|
| Mice, Inbred C3H | 6 | 2004 | 38 | 0.300 |
Why?
|
| Drug Synergism | 4 | 2011 | 24 | 0.300 |
Why?
|
| Fungi | 1 | 2006 | 2 | 0.290 |
Why?
|
| Coculture Techniques | 3 | 2018 | 5 | 0.290 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2005 | 13 | 0.290 |
Why?
|
| Methylnitronitrosoguanidine | 2 | 2016 | 4 | 0.280 |
Why?
|
| Enzyme Activation | 4 | 2008 | 29 | 0.270 |
Why?
|
| B7-1 Antigen | 2 | 2018 | 3 | 0.270 |
Why?
|
| B7-2 Antigen | 2 | 2018 | 3 | 0.270 |
Why?
|
| HLA-DR Antigens | 2 | 2018 | 3 | 0.270 |
Why?
|
| Blotting, Western | 4 | 2009 | 116 | 0.270 |
Why?
|
| Tongue Neoplasms | 1 | 2005 | 1 | 0.270 |
Why?
|
| Colonic Neoplasms | 1 | 2005 | 4 | 0.270 |
Why?
|
| Methylcholanthrene | 3 | 1997 | 3 | 0.260 |
Why?
|
| Caspases | 4 | 2005 | 21 | 0.260 |
Why?
|
| Aggregatibacter actinomycetemcomitans | 1 | 2004 | 2 | 0.250 |
Why?
|
| Gamma Rays | 3 | 2013 | 6 | 0.250 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 14 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 77 | 0.250 |
Why?
|
| Leukemia, T-Cell | 1 | 2003 | 1 | 0.250 |
Why?
|
| fas Receptor | 1 | 2003 | 3 | 0.240 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 6 | 0.240 |
Why?
|
| Tumor Cells, Cultured | 3 | 2014 | 67 | 0.230 |
Why?
|
| Radiation-Protective Agents | 2 | 2013 | 3 | 0.230 |
Why?
|
| Treatment Outcome | 2 | 2013 | 119 | 0.230 |
Why?
|
| Oxidation-Reduction | 2 | 2015 | 12 | 0.220 |
Why?
|
| Hesperidin | 1 | 2022 | 1 | 0.220 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2022 | 1 | 0.220 |
Why?
|
| Receptor, Insulin | 1 | 2022 | 6 | 0.220 |
Why?
|
| Carbohydrate Metabolism | 1 | 2022 | 8 | 0.220 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 12 | 0.220 |
Why?
|
| Plant Extracts | 1 | 2022 | 6 | 0.220 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2022 | 31 | 0.210 |
Why?
|
| Quercetin | 1 | 2022 | 10 | 0.210 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2021 | 1 | 0.210 |
Why?
|
| Myxovirus Resistance Proteins | 1 | 2021 | 1 | 0.210 |
Why?
|
| Seasons | 1 | 2021 | 2 | 0.210 |
Why?
|
| Egypt | 1 | 2021 | 3 | 0.210 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2021 | 5 | 0.210 |
Why?
|
| Cholera Toxin | 1 | 2021 | 1 | 0.210 |
Why?
|
| Ovalbumin | 1 | 2021 | 1 | 0.210 |
Why?
|
| Ubiquitins | 1 | 2021 | 13 | 0.210 |
Why?
|
| Lung | 1 | 2021 | 12 | 0.210 |
Why?
|
| Intestine, Small | 1 | 2021 | 7 | 0.210 |
Why?
|
| Pilot Projects | 1 | 2021 | 28 | 0.210 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 30 | 0.210 |
Why?
|
| Aspartate Aminotransferases | 1 | 2021 | 2 | 0.210 |
Why?
|
| Liver Function Tests | 1 | 2021 | 4 | 0.210 |
Why?
|
| Alanine Transaminase | 1 | 2021 | 10 | 0.210 |
Why?
|
| Incidence | 1 | 2021 | 55 | 0.210 |
Why?
|
| Epithelial Cells | 1 | 2021 | 29 | 0.210 |
Why?
|
| tau Proteins | 1 | 2021 | 2 | 0.210 |
Why?
|
| Insulin | 1 | 2022 | 109 | 0.200 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 83 | 0.200 |
Why?
|
| Age Factors | 2 | 2020 | 90 | 0.200 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2021 | 1 | 0.200 |
Why?
|
| Toxicity Tests, Acute | 1 | 2021 | 1 | 0.200 |
Why?
|
| Plaque, Amyloid | 1 | 2021 | 1 | 0.200 |
Why?
|
| Antioxidant Response Elements | 1 | 2021 | 1 | 0.200 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2021 | 3 | 0.200 |
Why?
|
| Down-Regulation | 2 | 2016 | 52 | 0.200 |
Why?
|
| Behavior, Animal | 1 | 2021 | 24 | 0.200 |
Why?
|
| Diet | 2 | 2019 | 40 | 0.200 |
Why?
|
| Rana pipiens | 4 | 1990 | 4 | 0.190 |
Why?
|
| Maze Learning | 1 | 2020 | 1 | 0.190 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2010 | 3 | 0.190 |
Why?
|
| Janus Kinase 2 | 1 | 2020 | 2 | 0.190 |
Why?
|
| Pregnancy | 1 | 2021 | 305 | 0.190 |
Why?
|
| Hippocampus | 1 | 2020 | 13 | 0.190 |
Why?
|
| Autophagy | 1 | 2020 | 10 | 0.190 |
Why?
|
| Seeds | 1 | 2020 | 1 | 0.190 |
Why?
|
| Diethylnitrosamine | 1 | 2020 | 4 | 0.190 |
Why?
|
| Chemoprevention | 1 | 2020 | 5 | 0.190 |
Why?
|
| STAT3 Transcription Factor | 1 | 2020 | 21 | 0.190 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 12 | 0.190 |
Why?
|
| X-Rays | 1 | 2019 | 1 | 0.190 |
Why?
|
| DNA Fragmentation | 1 | 2019 | 7 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 11 | 0.190 |
Why?
|
| Reactive Oxygen Species | 2 | 2010 | 36 | 0.180 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 93 | 0.180 |
Why?
|
| Anti-HIV Agents | 1 | 1998 | 8 | 0.160 |
Why?
|
| Polysaccharides | 1 | 1998 | 2 | 0.160 |
Why?
|
| HIV-1 | 1 | 1998 | 10 | 0.160 |
Why?
|
| Crystallization | 1 | 2018 | 1 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 28 | 0.160 |
Why?
|
| Carcinogens | 1 | 1997 | 4 | 0.160 |
Why?
|
| Nerve Growth Factor | 1 | 2017 | 1 | 0.150 |
Why?
|
| TRPV Cation Channels | 1 | 2017 | 4 | 0.150 |
Why?
|
| Amino Acid Chloromethyl Ketones | 2 | 2008 | 2 | 0.150 |
Why?
|
| Ribavirin | 1 | 2016 | 1 | 0.150 |
Why?
|
| Caspase Inhibitors | 2 | 2008 | 5 | 0.150 |
Why?
|
| Viral Load | 1 | 2016 | 6 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 17 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 30 | 0.150 |
Why?
|
| Nitric Oxide | 2 | 2009 | 54 | 0.150 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2016 | 1 | 0.150 |
Why?
|
| Drug Agonism | 1 | 2016 | 1 | 0.150 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2016 | 9 | 0.150 |
Why?
|
| Gastric Mucosa | 1 | 2016 | 2 | 0.150 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2016 | 7 | 0.150 |
Why?
|
| Respiratory Burst | 2 | 2008 | 2 | 0.140 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 2010 | 3 | 0.140 |
Why?
|
| Integrin alpha Chains | 1 | 2015 | 1 | 0.140 |
Why?
|
| B-Lymphocytes | 2 | 2009 | 7 | 0.130 |
Why?
|
| Free Radicals | 1 | 2015 | 2 | 0.130 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2014 | 1 | 0.130 |
Why?
|
| Interferons | 1 | 2014 | 2 | 0.130 |
Why?
|
| Membrane Potentials | 2 | 2004 | 11 | 0.120 |
Why?
|
| HL-60 Cells | 1 | 2014 | 1 | 0.120 |
Why?
|
| Drug Resistance, Multiple | 1 | 2014 | 2 | 0.120 |
Why?
|
| Leukocytes | 3 | 1990 | 4 | 0.120 |
Why?
|
| Cichlids | 1 | 2013 | 1 | 0.120 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2013 | 2 | 0.120 |
Why?
|
| Monocytes | 2 | 2010 | 13 | 0.120 |
Why?
|
| Survival Rate | 1 | 2013 | 23 | 0.120 |
Why?
|
| Radiation Dosage | 1 | 2013 | 3 | 0.120 |
Why?
|
| California | 1 | 2013 | 93 | 0.110 |
Why?
|
| Prevalence | 1 | 2013 | 114 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 246 | 0.110 |
Why?
|
| Risk Factors | 1 | 2013 | 240 | 0.110 |
Why?
|
| CD40 Antigens | 1 | 2011 | 2 | 0.110 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1991 | 5 | 0.110 |
Why?
|
| Immunoglobulins | 1 | 2011 | 4 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2011 | 17 | 0.100 |
Why?
|
| Ethiodized Oil | 1 | 2010 | 2 | 0.100 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2010 | 2 | 0.100 |
Why?
|
| Catheter Ablation | 1 | 2010 | 2 | 0.100 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 5 | 0.100 |
Why?
|
| alpha-Fetoproteins | 1 | 2010 | 5 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 10 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2010 | 10 | 0.100 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 22 | 0.100 |
Why?
|
| Fishes | 2 | 1988 | 6 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 62 | 0.100 |
Why?
|
| Vitiligo | 2 | 1987 | 2 | 0.100 |
Why?
|
| Trialkyltin Compounds | 1 | 1990 | 1 | 0.100 |
Why?
|
| Thyrotropin | 1 | 2010 | 6 | 0.100 |
Why?
|
| Weight Gain | 1 | 2010 | 10 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2010 | 19 | 0.100 |
Why?
|
| Neoplasms, Experimental | 2 | 1987 | 7 | 0.100 |
Why?
|
| Housing, Animal | 1 | 2010 | 2 | 0.090 |
Why?
|
| Diamond | 1 | 2010 | 2 | 0.090 |
Why?
|
| Adolescent | 5 | 2000 | 305 | 0.090 |
Why?
|
| Ethanol | 1 | 2010 | 52 | 0.090 |
Why?
|
| Anura | 1 | 1990 | 5 | 0.090 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2009 | 1 | 0.090 |
Why?
|
| Drinking | 1 | 2009 | 8 | 0.090 |
Why?
|
| Cell Count | 1 | 2009 | 10 | 0.090 |
Why?
|
| Lipopolysaccharides | 1 | 2009 | 20 | 0.090 |
Why?
|
| Phenotype | 1 | 2009 | 40 | 0.090 |
Why?
|
| Cell Shape | 1 | 2009 | 3 | 0.090 |
Why?
|
| Trypan Blue | 1 | 2009 | 1 | 0.090 |
Why?
|
| Beverages | 1 | 2009 | 3 | 0.090 |
Why?
|
| Hydrogen Peroxide | 1 | 2009 | 5 | 0.090 |
Why?
|
| Cytoplasm | 1 | 2008 | 6 | 0.090 |
Why?
|
| Caspase 9 | 1 | 2008 | 6 | 0.080 |
Why?
|
| Caspase 8 | 1 | 2008 | 4 | 0.080 |
Why?
|
| Cyprinodontiformes | 1 | 1988 | 1 | 0.080 |
Why?
|
| Oryzias | 1 | 1988 | 1 | 0.080 |
Why?
|
| Radiation Injuries, Experimental | 1 | 1988 | 1 | 0.080 |
Why?
|
| Bacteria | 1 | 2008 | 2 | 0.080 |
Why?
|
| Aggression | 1 | 1988 | 4 | 0.080 |
Why?
|
| Injections, Intraperitoneal | 1 | 2008 | 10 | 0.080 |
Why?
|
| Random Allocation | 1 | 2008 | 15 | 0.080 |
Why?
|
| Estrogens | 1 | 1988 | 25 | 0.080 |
Why?
|
| Lymphokines | 1 | 1987 | 11 | 0.080 |
Why?
|
| Stress, Physiological | 1 | 1987 | 10 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 16 | 0.080 |
Why?
|
| Propionibacterium acnes | 1 | 1987 | 2 | 0.080 |
Why?
|
| Mice, Nude | 1 | 2007 | 36 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1988 | 77 | 0.080 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 1986 | 1 | 0.080 |
Why?
|
| Pharyngeal Neoplasms | 1 | 1986 | 1 | 0.080 |
Why?
|
| Laryngeal Neoplasms | 1 | 1986 | 3 | 0.080 |
Why?
|
| Mycelium | 1 | 2006 | 1 | 0.070 |
Why?
|
| Cortisone | 1 | 1986 | 1 | 0.070 |
Why?
|
| Thymus Gland | 1 | 1986 | 1 | 0.070 |
Why?
|
| Desoxycorticosterone | 1 | 1986 | 4 | 0.070 |
Why?
|
| Neoplasms | 1 | 1987 | 54 | 0.070 |
Why?
|
| U937 Cells | 1 | 2005 | 1 | 0.070 |
Why?
|
| Caco-2 Cells | 1 | 2005 | 2 | 0.070 |
Why?
|
| Protein Kinases | 2 | 1997 | 4 | 0.070 |
Why?
|
| Interleukin-2 | 2 | 2000 | 10 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2005 | 10 | 0.070 |
Why?
|
| Macrophage Activation | 1 | 2004 | 2 | 0.060 |
Why?
|
| Stimulation, Chemical | 1 | 2004 | 14 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2004 | 21 | 0.060 |
Why?
|
| Intracellular Membranes | 1 | 2004 | 6 | 0.060 |
Why?
|
| Leukocyte Count | 3 | 1990 | 3 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 19 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 45 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 179 | 0.060 |
Why?
|
| Time Factors | 2 | 2003 | 120 | 0.060 |
Why?
|
| Carbohydrates | 2 | 1997 | 6 | 0.060 |
Why?
|
| Acid Phosphatase | 1 | 2003 | 4 | 0.060 |
Why?
|
| K562 Cells | 1 | 2003 | 3 | 0.060 |
Why?
|
| Cell Adhesion | 2 | 1991 | 13 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2000 | 5 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2000 | 8 | 0.050 |
Why?
|
| Probability | 1 | 2000 | 16 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2000 | 7 | 0.050 |
Why?
|
| Carbohydrate Sequence | 1 | 1998 | 1 | 0.040 |
Why?
|
| Cell Fusion | 1 | 1998 | 1 | 0.040 |
Why?
|
| HIV Core Protein p24 | 1 | 1998 | 1 | 0.040 |
Why?
|
| Virus Replication | 1 | 1998 | 4 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 1998 | 62 | 0.040 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 1997 | 2 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 1997 | 3 | 0.040 |
Why?
|
| RNA | 1 | 1997 | 16 | 0.040 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1997 | 1 | 0.040 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 1997 | 1 | 0.040 |
Why?
|
| Phosphatidylinositol 4,5-Diphosphate | 1 | 1997 | 1 | 0.040 |
Why?
|
| Lectins | 1 | 1997 | 4 | 0.040 |
Why?
|
| Immune Tolerance | 2 | 1988 | 5 | 0.040 |
Why?
|
| Erythrocytes | 2 | 1987 | 9 | 0.040 |
Why?
|
| Isoquinolines | 1 | 1991 | 2 | 0.030 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1991 | 2 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 1991 | 12 | 0.030 |
Why?
|
| Piperazines | 1 | 1991 | 24 | 0.030 |
Why?
|
| Autoantibodies | 2 | 1987 | 3 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 1987 | 2 | 0.020 |
Why?
|
| Tin | 1 | 1990 | 1 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 1987 | 5 | 0.020 |
Why?
|
| Child | 2 | 1987 | 126 | 0.020 |
Why?
|
| Bufonidae | 1 | 1990 | 1 | 0.020 |
Why?
|
| Rana catesbeiana | 1 | 1990 | 6 | 0.020 |
Why?
|
| Genetic Variation | 1 | 1990 | 7 | 0.020 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 1988 | 2 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 1988 | 3 | 0.020 |
Why?
|
| Lymphotoxin-alpha | 1 | 1987 | 1 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1987 | 2 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1987 | 38 | 0.020 |
Why?
|
| Naloxone | 1 | 1987 | 14 | 0.020 |
Why?
|
| Chloroquine | 1 | 1987 | 1 | 0.020 |
Why?
|
| Glutaral | 1 | 1987 | 1 | 0.020 |
Why?
|
| Isoantigens | 1 | 1987 | 1 | 0.020 |
Why?
|
| Trypsin | 1 | 1987 | 2 | 0.020 |
Why?
|
| Mitogens | 1 | 1987 | 2 | 0.020 |
Why?
|
| Erythrocyte Count | 1 | 1987 | 2 | 0.020 |
Why?
|
| Granulocytes | 1 | 1987 | 2 | 0.020 |
Why?
|
| Cycloheximide | 1 | 1987 | 4 | 0.020 |
Why?
|
| Colchicine | 1 | 1987 | 3 | 0.020 |
Why?
|
| Chelating Agents | 1 | 1987 | 2 | 0.020 |
Why?
|
| Glycoproteins | 1 | 1987 | 4 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1987 | 14 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 1987 | 17 | 0.020 |
Why?
|
| 2-Aminopurine | 1 | 1997 | 1 | 0.010 |
Why?
|
| Antimetabolites | 1 | 1997 | 2 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1997 | 35 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 34 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1986 | 14 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1986 | 19 | 0.000 |
Why?
|